Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting With FDA For Oral APX3330 In Diabetic Retinopathy, Agreement on Phase 3 Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma has announced a successful end-of-Phase 2 meeting with the FDA for oral APX3330 in Diabetic Retinopathy. The company and the FDA have agreed on the Phase 3 primary endpoint.
November 02, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocuphire Pharma's successful end-of-Phase 2 meeting with the FDA for oral APX3330 in Diabetic Retinopathy and agreement on Phase 3 primary endpoint could potentially boost the company's stock.
The successful end-of-Phase 2 meeting with the FDA and agreement on the Phase 3 primary endpoint for oral APX3330 in Diabetic Retinopathy is a significant milestone for Ocuphire Pharma. This could potentially lead to a positive market reaction, boosting the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100